{
    "Trade/Device Name(s)": [
        "WaveSense KeyNote Codeless Blood Glucose Monitoring System",
        "Blood Glucose Monitoring System",
        "Glucose Test System"
    ],
    "Submitter Information": "AgaMatrix, Inc.",
    "510(k) Number": "K073573",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "CGA"
    ],
    "Summary Letter Date": "January 16, 2008",
    "Summary Letter Received Date": "January 18, 2008",
    "Submission Date": "December 6, 2007",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "WaveSense KeyNote Codeless Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for the AgaMatrix WaveSense KeyNote Codeless Blood Glucose Monitoring System intended for quantitative measurement of glucose in capillary whole blood.",
    "Indications for Use Summary": "For quantitative measurement of glucose in fresh capillary whole blood from finger, palm, or forearm; for home use by persons with diabetes or in clinical settings as an aid to monitor diabetes control.",
    "fda_folder": "Clinical Chemistry"
}